Ligand Pharmaceuticals Inc (OQ:LGND)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 3911 Sorrento Valley Blvd, Suite 110
Tel: N/A
IR: See website
Key People
Matthew Edward Korenberg
President, Chief Operating Officer
Todd C. Davis
Chief Executive Officer, Director
Octavio Espinoza
Chief Financial Officer
Andrew Reardon
Chief Legal Officer
Business Overview
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. It also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program.
Financial Overview
For the nine months ended 30 September 2023, Ligand Pharmaceuticals Inc revenues decreased 33% to $103.2M. Net income before extraordinary items totaled $35.6M vs. loss of $4.2M. Revenues reflect Captisol decrease of 68% to $24.5M, Contract revenue decrease of 30% to $17.3M. Net Income reflects Gain (loss) from short-term investments increase from $15.7M (expense) to $30.3M (income), Research and Development decrease of 50% to $13.7M (expense).
Employees: 76 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $880.07M as of Sep 30, 2023
Annual revenue (TTM): $130.26M as of Sep 30, 2023
EBITDA (TTM): $64.10M as of Sep 30, 2023
Net annual income (TTM): $46.29M as of Sep 30, 2023
Free cash flow (TTM): $79.34M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,435,958 as of Nov 6, 2023
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.